Get your free copy of our MACS&more Anniversary Edition

Distinguished scientists present their results and perspectives on some of today’s most promising approaches to cellular therapies, involving regulatory T cells, NK cells, stem cells, neural cells, and CAR-expressing T cells.

Read on how Miltenyi Biotec revolutionized cell processing for both basic research and clinical application, and learn about a complete solution to uncover the full potential of xenograft technology.

The high-quality print version contains two fold-out pages highlighting the milestones that got us where we are today, and the breakthroughs that inspire us for tomorrow.

MACS&more Vol 16-1, 2014

Get your electronic version of the MACS&more 16-1/2014 Anniversary Edition below. You can view it with a reader app that’s also compatible with both Android and Apple devices. Simply follow the link on your computer or mobile device.

 ► MACS&more Vol 16-1, 2014

Topics of the MACS&more Anniversary Edition include:
► Treg cells in solid organ transplantation 
    Cell manufacture for clinical studies 
► NK cell transplantation 
    Consolidation therapy in children with acute myeloid leukemia – a pilot study 
► Tackling autoimmune diseases 
    Resetting the immune system is associated with long-term remission
► Neural cells for tissue regeneration research 
    Differentiation from PSCs and subsequent isolation
► Chimeric antigen receptor–expressing T cells 
    Holding great promise for cancer immunotherapy
► The way to integrated cell processing 
    25 years of development and innovation at Miltenyi Biotec
► A leap forward in cancer research 
    Effective mouse cell depletion enables accurate, unbiased analysis of tumor xenografts 

Find additional MACS&more issues here


Customer login


Forgot password?
Register for account

0 Shopping cart


Miltenyi Biotec Inc.
Phone: +1 800 FOR MACS
Fax:+1 877 591 1060
Contact overview

Product finder

Antibody panel builder



EBMT 2018 Symposium

EBMT 2018 Symposium

Change country

Please select your country to continue